Showing results (111-120 of 129) with videos related to
Sort By:
Pageof 13
EJNMMI Radiopharmacy and Chemistry|July 31, 2020
Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelatorsEuy Sung Moon, Filipe Elvas, Gwendolyn Vliegen, et al.Journal of Leukocyte Biology|July 10, 2025
Fibroblast activation protein on human natural killer cells: insights from natural killer cell activation and crosstalk with cancer-associated fibroblastsYentl Van Rymenant, Anke de Groot, Laura Dirkx, et al.Life Science Alliance|February 6, 2019
DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophagesNathalia M de Vasconcelos, Gwendolyn Vliegen, Amanda Gonçalves, et al.Pharmaceutics|June 2, 2021
Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in RatsNikita Hanning, Michelle De Bruyn, Hannah Ceuleers, et al.Frontiers in Pharmacology|June 20, 2022
The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal InsultHannah Ceuleers, Nikita Hanning, Michelle De Bruyn, et al.Frontiers in Immunology|September 21, 2018
Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 ActivityRik Janssens, Daiane Boff, Pieter Ruytinx, et al.Journal of Medicinal Chemistry|April 24, 2024
Druglike, 18F-labeled PET Tracers Targeting Fibroblast Activation ProteinMuhammet Tanc, Nicolò Filippi, Yentl Van Rymenant, et al.British Journal of Pharmacology|June 19, 2018
Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndromeHannah Ceuleers, Nikita Hanning, Jelena Heirbaut, et al.Scientific Reports|October 15, 2020
A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammationCedric Joossen, Adrienn Baán, Carlos Moreno-Cinos, et al.Journal of Medicinal Chemistry|October 14, 2025
Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic PotentialPawel Brzeminski, Emile Verhulst, Adrian Fabisiak, et al.Pageof 13